Sicene and technology company Merck is to acquire Chord Therapeutics (Chord), a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, launched in October 2020 by leadng healthcare venture capital firm Omega Funds, the sole investor in the Company’s USD 16 million Series A financing.
The strategic acquisition enables Merck to expand its neurology pipeline to develop Chord’s lead drug candidate, CRD1 (cladribine), for the treatment of gMG and NMOSD
